RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037 · see citing works

Lysosomal cell death at a glance

Aits, S., & Jäättelä, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.091181 · Cited by 667 · see citing works

Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology

Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519 · see citing works

Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

Tai, Y., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J. L., Yates, J. W., Gliddon, L., Fieles, W. E., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 485 · see citing works

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472 · see citing works

Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues

Droga-Mazovec, G., Bojič, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, G. S., Stoka, V., Turk, V., & Turk, B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802513200 · Cited by 399 · see citing works

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342 · see citing works

Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase

Petersen, N. H. T., Olsen, O. D., Groth‐Pedersen, L., Ellegaard, A., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.003 · Cited by 335 · see citing works

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333 · see citing works

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M. R., Munshi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.115 · Cited by 309 · see citing works

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, H. T. C., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294 · see citing works

Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation

Conus, S., Perozzo, R., Reinheckel, T., Peters, C., Scapozza, L., Yousefi, S., & Simon, H. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072152 · Cited by 262 · see citing works

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

Kumar, S. K., Fonseca, R., Ketterling, R. P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dingli, D., Knudson, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390658 · Cited by 253 · see citing works

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

Kim, D., Wang, J., Willingham, S. B., Martin, R. K., Wernig, G., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.141 · Cited by 249 · see citing works

CD20‐mediated apoptosis: signalling through lipid rafts

Deans, J. P., Li, H., & Polyak, M. J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01495.x · Cited by 235 · see citing works

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Bataille, R., Jégo, G., Robillard, N., Barillé‐Nion, S., Harousseau, J., Moreau, P., Amiot, M., & Pellat‐Deceunynck, C. (2006) · PubMed · Cited by 225 · see citing works

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Avet‐Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A., Voillat, L., Wetterwald, M., Pegourié, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5726 · Cited by 223 · see citing works

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Lammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., Ortiz Buijsse, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3474.3474 · Cited by 222 · see citing works

Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis

Erdal), D. H. K. (., Berndtsson, M., Castro, J., Brunk, U. T., Shoshan, M. C., & Linder, S. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408592102 · Cited by 218 · see citing works

Current treatment landscape for relapsed and/or refractory multiple myeloma

Dimopoulos, M. A., Richardson, P. G. G., Moreau, P., & Anderson, K. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 195 · see citing works

Combating apoptosis and multidrug resistant cancers by targeting lysosomes

Groth‐Pedersen, L., & Jäättelä, M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.05.021 · Cited by 192 · see citing works

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Reece, D. E., Song, K., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C. I., Masih‐Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 185 · see citing works

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, H. T. C., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177 · see citing works

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients

Jurišić, V., Srdić‐Rajić, T., Konjević, G. M., Marković, O., & Čolović, M. (2007) · Medical Oncology · doi:10.1007/s12032-007-0007-y · Cited by 147 · see citing works

Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death

Giraldo, A. M. V., Appelqvist, H., Ederth, T., & Öllinger, K. M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140145 · Cited by 131 · see citing works

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

Honeychurch, J., Alduaij, W., Azizyan, M., Cheadle, E. J., Pelicano, H., Ivanov, A., Huang, P., Cragg, M. S., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2011-12-395541 · Cited by 130 · see citing works

CD38/CD19: a lipid raft–dependent signaling complex in human B cells

Deaglio, S., Vaisitti, T., Billington, R. A., Bergui, L., Omedè, P., Genazzani, A. A., & Malavasi, F. (2007) · Blood · doi:10.1182/blood-2006-12-061812 · Cited by 118 · see citing works

CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells

Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.140 · Cited by 108 · see citing works

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Leleu, X. P., Karlin, L., Macro, M., Hulin, C., Garderet, L., Roussel, M., Arnulf, B., Pegourié, B., Kolb, B., Stoppa, A. M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612069 · Cited by 100 · see citing works

p53 haploinsufficiency and functional abnormalities in multiple myeloma

Teoh, P. J., Chung, T., Sebastian, S., Choo, S., Yan, J., Ng, S., Fonseca, R., & Chng, W. J. (2014) · Leukemia · doi:10.1038/leu.2014.102 · Cited by 80 · see citing works

Therapeutic Advancements in Multiple Myeloma

Gozzetti, A., Candi, V., Papini, G., & Bocchia, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00241 · Cited by 67 · see citing works

Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule

Chillemi, A., Zaccarello, G., Quarona, V., Ferracin, M., Ghimenti, C., Massaia, M., Horenstein, A. L., & Malavasi, F. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00009 · Cited by 63 · see citing works

Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies

Kapoor, P., Fonseca, R., Rajkumar, S. V., Sinha, S., Gertz, M. A., Stewart, A. K., Bergsagel, P. L., Lacy, M. Q., Dingli, D., Ketterling, R. P., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0677 · Cited by 61 · see citing works

Daratumumab granted breakthrough drug status

Laubach, J. P., Tai, Y., Richardson, P. G. G., & Anderson, K. C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.889681 · Cited by 57 · see citing works

Antibody-Based Therapies in Multiple Myeloma

Tai, Y., & Anderson, K. C. (2011) · Bone Marrow Research · doi:10.1155/2011/924058 · Cited by 52 · see citing works

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma

Berdeja, J. G. (2014) · Frontiers in bioscience · doi:10.2741/4202 · Cited by 46 · see citing works

The development of potential antibody-based therapies for myeloma

Sherbenou, D. W., Behrens, C. R., Yang, S., Wolf, J. L., Martin, T. G., & Liu, B. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.09.011 · Cited by 39 · see citing works

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Martin, T. G., Baz, R., Benson, D. M., Lendvai, N. K., Campana, F., Charpentier, E., & Vij, R. (2014) · Blood · doi:10.1182/blood.v124.21.83.83 · Cited by 38 · see citing works

Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton

Barbier, S., Châtre, L., Bras, M. L., Sancho, P., Roué, G., Virely, C., Yuste, V. J., Baudet, S., Rubio, M., Esquerda, J. E., et al. (2009) · Haematologica · doi:10.3324/haematol.13690 · Cited by 34 · see citing works

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

Breton, C. S., Nahimana, A., Aubry, D., Macoin, J., Moretti, P., Bertschinger, M., Hou, S. Y., Duchosal, M. A., & Back, J. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-33 · Cited by 31 · see citing works

MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells

Drénou, B., Amiot, L., Setterblad, N., Taque, S., Guilloux, V., Charron, D. J., Fauchet, R., & Mooney, N. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0704423 · Cited by 28 · see citing works

Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing δ/λ type immunoglobulin

Matsuo, Y., Drexler, H. G., Harashima, A., Okochi, A., Hasegawa, A., Kojima, K., & Orita, K. (2004) · Leukemia Research · doi:10.1016/j.leukres.2003.12.008 · Cited by 19 · see citing works

Elotuzumab for the Treatment of Multiple Myeloma

Moreau, P., & Touzeau, C. (2014) · Future Oncology · doi:10.2217/fon.14.56 · Cited by 9 · see citing works

Choosing treatment options for patients with relapsed/refractory multiple myeloma

Castelli, R., Orofino, N., Losurdo, A., Gualtierotti, R., & Cugno, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.863153 · Cited by 6 · see citing works

Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.

Singh, A. T. K., Evens, A. M., Prachand, S., & Gordon, L. I. (2010) · PubMed · Cited by 5 · see citing works

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648 · see citing works

CD38 antibodies in multiple myeloma: back to the future

van de Donk, N. W. C. J., Richardson, P. G. G., & Malavasi, F. (2017) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 495 · see citing works

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392 · see citing works

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 357 · see citing works

Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond

van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353 · see citing works

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Tai, Y., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 352 · see citing works

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297 · see citing works

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284 · see citing works

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252 · see citing works

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Moreno, L., Pérez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodríguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221 · see citing works

Lysosomal membrane permeabilization in cell death: new evidence and implications for health and disease

Serrano‐Puebla, A., & Boya, P. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12966 · Cited by 204 · see citing works

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication

An, G., Acharya, C., Feng, X., Wen, K., Zhong, M., Zhang, L., Munshi, N. C., Qiu, L., Tai, Y., & Anderson, K. C. (2016) · Blood · doi:10.1182/blood-2016-03-707547 · Cited by 184 · see citing works

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176 · see citing works

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166 · see citing works

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R. R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 162 · see citing works

Emerging immunotherapies in multiple myeloma

Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 157 · see citing works

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

Richardson, P. G. G., Perrot, A., Miguel, J. F. S., Beksaç, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00019-5 · Cited by 129 · see citing works

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127 · see citing works

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 121 · see citing works

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Zhu, C. Y., Song, Z., Wang, A., Srinivasan, S. S., Yang, G., Greco, R., Theilhaber, J., Shehu, E., Wu, L., Yang, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01771 · Cited by 117 · see citing works

The role of complement in the mechanism of action of therapeutic anti-cancer mAbs

Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104 · see citing works

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Bhatt, P. K., Kloock, C., & Comenzo, R. L. (2023) · Current Oncology · doi:10.3390/curroncol30020179 · Cited by 101 · see citing works

Immunomodulatory effects of CD38-targeting antibodies

van de Donk, N. W. C. J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.005 · Cited by 96 · see citing works

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 93 · see citing works

Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy

Domagała, A., Fidyt, K., Bobrowicz, M., Stachura, J., Szczygiel, K., & Firczuk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082256 · Cited by 91 · see citing works

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Mikhael, J. R., Richardson, P. G. G., Usmani, S. Z., Raje, N. S., Bensinger, W., Karanes, C., Campana, F., Kanagavel, D., Dubin, F., Liu, Q., et al. (2019) · Blood · doi:10.1182/blood-2019-02-895193 · Cited by 90 · see citing works

Anti CD38 monoclonal antibodies for multiple myeloma treatment

Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 89 · see citing works

CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies

Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019) · Cells · doi:10.3390/cells8121527 · Cited by 88 · see citing works

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Mikhael, J. R., Belhadj‐Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., Pour, L., Špıčka, I., Vij, R., Zonder, J. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00478-4 · Cited by 88 · see citing works

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84 · see citing works

Isatuximab: First Approval

Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01311-1 · Cited by 79 · see citing works

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Dimopoulos, M. A., Leleu, X. P., Moreau, P., Richardson, P. G. G., Liberati, A. M., Harrison, S. J., Prince, H. M., Ocio, E. M., Assadourian, S., Campana, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0868-z · Cited by 73 · see citing works

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71 · see citing works

CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging

Cui, H., Xie, N., Banerjee, S., Dey, T., Liu, R.-M., Antony, V. B., Sanders, Y. Y., Adams, T. S., Gómez, J. L., Thannickal, V. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2151oc · Cited by 70 · see citing works

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 69 · see citing works

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells

Matula, Z., Mikala, G., Lukácsi, S., Matkó, J., Kovács, T., Monostori, Ė., Uher, F., & Vályi-Nagy, I. (2021) · Cancers · doi:10.3390/cancers13143461 · Cited by 57 · see citing works

Immune Therapies in Multiple Myeloma

Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66 · see citing works

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Tai, Y., Cho, S., & Anderson, K. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01822 · Cited by 67 · see citing works

The Role of Cathepsin B in Pathophysiologies of Non-tumor and Tumor tissues: A Systematic Review

Wang, J., Zheng, M., Yang, X., Zhou, X., & Zhang, S. (2023) · Journal of Cancer · doi:10.7150/jca.86531 · Cited by 66 · see citing works

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

Díaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 65 · see citing works

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Joncour, V. L., Filppu, P., Hyvönen, M. L. K., Holopainen, M., Turunen, S. P., Sihto, H. J., Burghardt, I., Joensuu, H., Tynninen, O., Jääskeläinen, J. E., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809034 · Cited by 63 · see citing works

The lysosomal membrane protein Lamp2 alleviates lysosomal cell death by promoting autophagic flux in ischemic cardiomyocytes

Cui (2020) · doi:10.3389/fcell.2020.00031 · Cited by 62 · see citing works

Monoclonal antibody therapy in multiple myeloma

Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61 · see citing works

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

Xing, L., Lin, L., Yu, T., Li, Y., Cho, S., Liu, J., Wen, K., Hsieh, P. A., Kinneer, K., Munshi, N. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0745-9 · Cited by 60 · see citing works

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

Abramson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123924 · Cited by 59 · see citing works

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 58 · see citing works

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0857-2 · Cited by 54 · see citing works

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

Cho, S., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K. C., & Tai, Y. (2020) · Cancers · doi:10.3390/cancers12061473 · Cited by 54 · see citing works

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

Costa, F., Palma, B. D., & Giuliani, N. (2019) · Cells · doi:10.3390/cells8121632 · Cited by 51 · see citing works

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Bisht, K. K., Fukao, T., Chiron, M., Richardson, P. G. G., Atanackovic, D., Chini, E. N., Chng, W. J., de Velde, H. J. V., & Malavasi, F. (2023) · Cancer Medicine · doi:10.1002/cam4.6619 · Cited by 50 · see citing works

Immunotherapies targeting CD38 in Multiple Myeloma

Atanackovic, D., Steinbach, M. N., Radhakrishnan, S. V., & Luetkens, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1217374 · Cited by 51 · see citing works

Isatuximab: A Review of Its Use in Multiple Myeloma

Frampton, J. E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00827-0 · Cited by 51 · see citing works

Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells

Song, L., Wang, Z., Wang, Y., Guo, D., Yang, J., Chen, L., & Tan, N. (2017) · Molecules · doi:10.3390/molecules22111934 · Cited by 50 · see citing works

LRRK2 is required for CD38-mediated NAADP-Ca 2+ signaling and the downstream activation of TFEB (transcription factor EB) in immune cells

Nabar, N. R., Heijjer, C. N., Shi, C.-S., Hwang, I., Ganesan, S., Karlsson, M. C. I., & Kehrl, J. H. (2021) · Autophagy · doi:10.1080/15548627.2021.1954779 · Cited by 48 · see citing works

CD38 as an immunotherapeutic target in multiple myeloma

Bonello, F., D’Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & Gay, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1544240 · Cited by 50 · see citing works

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

Harrison, S. J., Perrot, A., Alegre, A. M., Simpson, D., Wang, M. C., Spencer, A. G., Delimpasi, S., Hulin, C., Sunami, K., Facon, T. T. F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17499 · Cited by 48 · see citing works

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46 · see citing works

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

Bonello, F., Mina, R., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers12010015 · Cited by 45 · see citing works

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Vincenti, F. G., Bestard, O., Brar, A., Cruzado, J. M., Serón, D., Gaber, A. O., Ali, N. M., Tambur, A. R., Lee, H., Abbadessa, G., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000287 · Cited by 44 · see citing works

Emerging trends and therapeutic applications of monoclonal antibodies

Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45 · see citing works

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00378-z · Cited by 43 · see citing works

Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma

Frerichs, K. A., Minnema, M. C., Levin, M., Broijl, A., Bos, G. M. J., Kersten, M. J., Mutis, T., Verkleij, C. P. M., Nijhof, I. S., Maas-Bosman, P. W. C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005220 · Cited by 43 · see citing works

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Zhang, L., Tai, Y., Ho, M., Qiu, L., & Anderson, K. C. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0081-6 · Cited by 42 · see citing works

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 41 · see citing works

New Biological Therapies for Multiple Myeloma

Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 46 · see citing works

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

de Acha, O. P., Reiman, L. T., Jayabalan, D. S., Walker, Z. J., Bosma, G., Keller, A. L., Parzych, S. E., Abbott, D., Idler, B. M., Ribadeneyra, D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010162 · Cited by 40 · see citing works

Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

Trudel, S., McCurdy, A. B. R., Louzada, M., Parkin, S., White, D. J., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02703-y · Cited by 40 · see citing works

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

Kinder, M., Bahlis, N. J., Malavasi, F., de Goeij, B. E. C. G., Babich, A., Sendecki, J. A., Rusbuldt, J. J., Bellew, K. M., Kane, C. M., & van de Donk, N. W. C. J. (2021) · Haematologica · doi:10.3324/haematol.2020.268656 · Cited by 40 · see citing works

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 40 · see citing works

Oxidative damage of lysosomes in regulated cell death systems: Pathophysiology and pharmacologic interventions

Nagakannan, P., Tabeshmehr, P., & Eftekharpour, E. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.001 · Cited by 39 · see citing works

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40 · see citing works

Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization

Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 38 · see citing works

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

Atanackovic, D., Yousef, S., Shorter, C., Tantravahi, S. K., Steinbach, M. N., Cardenas, F. I., Sborov, D. W., Radhakrishnan, S. V., Chiron, M., Miles, R. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0536-3 · Cited by 37 · see citing works

Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma

Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G. K., Russell, B. E., Li, W., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1077 · Cited by 37 · see citing works

Isatuximab for the treatment of relapsed/refractory multiple myeloma

Richardson, P. G. G., Beksaç, M., Špıčka, I., & Mikhael, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1841747 · Cited by 37 · see citing works

Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance

Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 38 · see citing works

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab

Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 35 · see citing works

CD38 as theranostic target in oncology

Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D’Huyvetter, M., Caers, J., & Marcion, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05768-6 · Cited by 34 · see citing works

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

Roccatello, D., Fenoglio, R., Sciascia, S., Naretto, C., Rossi, D., Ferro, M., Barreca, A., Malavasi, F., & Baldovino, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114129 · Cited by 34 · see citing works

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies

Wu, H., & Zhao, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68148 · Cited by 33 · see citing works

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment

Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34 · see citing works

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

Novellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 32 · see citing works

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Bringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31 · see citing works

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

Ugamraj, H. S., Dang, K. H., Ouisse, L., Buelow, B., Chini, E. N., Castello, G., Allison, J., Clarke, S., Davison, L. M., Buelow, R., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2095949 · Cited by 31 · see citing works

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Schjesvold, F. H., Richardson, P. G. G., Facon, T. T. F., Alegre, A. M., Spencer, A. G., Jurczyszyn, A. J., Sunami, K., Frenzel, L., Min, C., Guillonneau, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.253450 · Cited by 30 · see citing works

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Fau, J., Cheikh, R. E., Brillac, C., Koiwai, K., Mace, N., Campana, F., Sémiond, D., & Nguyen, L. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12561 · Cited by 30 · see citing works

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 30 · see citing works

CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers

Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 29 · see citing works

IFN-γ and CD38 in Hyperprogressive Cancer Development

Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 29 · see citing works

Targeting CD38 alleviates tumor-induced immunosuppression

Tai, Y., & Anderson, K. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22992 · Cited by 29 · see citing works

Emerging antibodies for the treatment of multiple myeloma

Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186644 · Cited by 29 · see citing works

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression

Xing, L., Wang, S., Liu, J., Yu, T., Chen, H., Wen, K., Li, Y., Lin, L., Hsieh, P. A., Cho, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1621 · Cited by 28 · see citing works

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Kumar, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.518 · Cited by 27 · see citing works

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Ocio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 27 · see citing works

Immunotherapy for the treatment of multiple myeloma

Jung, S., Lee, H., Vo, M.-C., Kim, H., & Lee, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.011 · Cited by 28 · see citing works

Novel Agents in Multiple Myeloma

Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27 · see citing works

Novel targets for the treatment of relapsing multiple myeloma

Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 27 · see citing works

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 26 · see citing works

SAR650984 (SAR) directly induces multiple myeloma (MM) cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by Pomalidomide

Jiang, H., An, G. C., Acharya, C., Feng, X., Wang, L., Cai, T., Song, Z., Yang, G., Adrian, F., Qiu, L., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.585 · Cited by 1 · see citing works

Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide

Jiang, H., Acharya, C., An, G. A. G., Feng, X., Song, Z., Yang, G., Adrián, F., Qiu, L., Richardson, P. G. G., Munshi, N. C., et al. (2015) · Blood · doi:10.1182/blood.v126.23.4253.4253

SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide

Jiang, H., An, G., Acharya, C., Zhong, M. Y., Cai, T., Song, Z., Yang, G., Adrián, F., Munshi, N. C., Tai, Y., et al. (2014) · Blood · doi:10.1182/blood.v124.21.2124.2124 · Cited by 3 · see citing works

A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.

Martin, T. G., Hsu, K., Strickland, S. A., Glenn, M. J., Mikhael, J. R., & Charpentier, E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8532 · Cited by 49 · see citing works

Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.

Hann, B. C., Cai, T., Wang, D., Hom, Y. K., Aftab, B. T., Martin, T. G., & Wolf, J. L. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5469 · Cited by 2 · see citing works